GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » 5-Year Yield-on-Cost %

BioXcel Therapeutics (FRA:BX2) 5-Year Yield-on-Cost % : 0.00 (As of May. 21, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics 5-Year Yield-on-Cost %?

BioXcel Therapeutics's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for BioXcel Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



FRA:BX2's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.615
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of BioXcel Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, BioXcel Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioXcel Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's 5-Year Yield-on-Cost % falls into.



BioXcel Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of BioXcel Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

BioXcel Therapeutics  (FRA:BX2) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


BioXcel Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioXcel Therapeutics (FRA:BX2) Business Description

Traded in Other Exchanges
Address
555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines